Related Experiment Video
Updated: Jul 10, 2026
06:09
Quantification of Tumor Cell Adhesion in Lymph Node Cryosections
Published on: February 9, 2020
[Lymphangiogenesis and tumor progression].
Daniel Vittet1, Jean-Jacques Feige
1Inserm U878, iRTSV/LAPV, CEA Grenoble, 17 rue des Martyrs, 38054 Grenoble Cedex 9. daniel.vittet@cea.fr
Bulletin Du Cancer
|October 30, 2007
Summary
Lymphangiogenesis, the formation of new lymphatic vessels, is linked to cancer metastasis. Targeting the VEGF-C/D and VEGFR3 pathway may block tumor spread and improve cancer treatment outcomes.
Area of Science:
- Oncology
- Vascular Biology
- Cancer Metastasis Research
Context:
- Recent advances in identifying lymphatic endothelial cell-specific markers have enabled detailed studies on lymphangiogenesis.
- Lymphangiogenesis is increasingly recognized for its role in tumor progression and metastasis.
- The VEGF-C/D and VEGFR3 signaling pathway is a key regulator of lymphangiogenesis.
Purpose:
- To investigate the role of lymphangiogenesis in cancer metastasis.
- To explore the therapeutic potential of targeting lymphangiogenesis and its regulatory pathways.
- To highlight the need for further research into the prognostic value of lymphangiogenesis and anti-lymphangiogenic therapies.
Summary:
- Functional links exist between lymphangiogenesis, lymph node invasion, and metastasis.
- Vascular Endothelial Growth Factor-C (VEGF-C) and VEGF-D, activating the VEGFR3 receptor, are crucial in regulating lymphangiogenesis.
- Inhibiting tumoral lymphangiogenesis via this pathway is a potential strategy to impede metastatic development.
Impact:
- Identifies lymphangiogenesis as a critical factor in cancer metastasis.
- Suggests therapeutic strategies targeting the VEGF-C/D-VEGFR3 pathway for anti-metastasis treatment.
- Emphasizes the need for further clinical studies to validate lymphangiogenesis as a prognostic marker and anti-lymphangiogenic therapies.
More Related Videos
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:15Development of the Lymphatic System
The development of lymphatic tissues and vessels in embryonic life begins around the fifth week. These structures originate from the mesoderm layer, with lymph sacs emerging from developing veins.
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...
The first lymph sacs to form are the paired jugular lymph sacs located at the junction of the internal jugular and subclavian veins. From these sacs, lymphatic capillary plexuses extend to the thorax, upper limbs, neck, and head, eventually forming lymphatic vessels. Each jugular lymph sac maintains a...